ReviewAlzheimer's & dementia (Amsterdam, Netherlands)
Tears as a window to Alzheimer's disease: A systematic review of biomarkers for early detection.
Review in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fast nanoDSF Tear Fluid Profiling: Toward Diagnosis of Age-Related Macular Degeneration.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the leading cause of dementia, characterized by the accumulation of amyloid beta and tau proteins, leading to neuronal degeneration and brain atrophy. While cerebrospinal fluid and blood biomarkers have advanced early AD diagnosis, these methods are invasive and costly. This systematic review investigates tears as a non-invasive, accessible source of AD biomarkers. Using tears, directly linked to the central nervous system, we can effectively detect proteins, microRNA (miRNA), and extracellular vesicles (EVs), reflecting neurodegenerative processes. Tear collection is cost effective and minimally stressful, allowing continuous biomarker monitoring across disease stages. This review highlights recent findings on specific proteins, miRNA, and EVs in tears of patients with AD, and examines tear collection and analysis methods. The potential of these techniques for early, accessible disease detection is emphasized. Further research is needed to standardize methods and validate biomarkers in larger cohorts, positioning tears as a valuable tool for early AD diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.